Skip to main
ANTX
ANTX logo

ANTX Stock Forecast & Price Target

ANTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AN2 Therapeutics Inc's promising outlook is supported by favorable safety and tolerability data for its lead candidate, epetraborole, which showed mild and reversible reductions in hemoglobin during Phase 2 trials. Positive clinical outcomes, including significant improvements in cough frequency and intensity for patients suffering from Mycobacterium avium complex non-tuberculous mycobacterial infections, underscore the drug’s potential impact on patient quality of life. Additionally, the encouraging pre-clinical data regarding epetraborole’s potential effectiveness against Mycobacterium abscessus, a more challenging target, positions AN2 Therapeutics to potentially expand its treatment offerings in a market with significant unmet medical needs.

Bears say

AN2 Therapeutics Inc. faces significant financial challenges, highlighted by a history of losses and the absence of profitability, which raises concerns about the sustainability of its operations. The company's recent setbacks in clinical trials, specifically with epetraborole, as well as the potential for litigation risks, further complicate its path to market. Additionally, the ongoing difficulty in establishing acceptable partnership terms for commercialization underscores a precarious position amid competitive market conditions and regulatory hurdles.

ANTX has been analyzed by 6 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AN2 Therapeutics Inc (ANTX) Forecast

Analysts have given ANTX a Buy based on their latest research and market trends.

According to 6 analysts, ANTX has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AN2 Therapeutics Inc (ANTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.